PT-141
PT-141 (Bremelanotide)
A melanocortin receptor agonist FDA-approved as Vyleesi for HSDD. Works centrally in the brain rather than peripherally like Viagra.
Typical Cost
$900-1200/month (Vyleesi), $50-100/vial (research)
Status
Research
Peptide Profile
PT-141
Mechanism of Action
Activates MC3R and MC4R receptors in brain regions controlling sexual desire and arousal. Increases dopamine in reward pathways. Central mechanism vs peripheral vasodilation.
Common Dosages
subcutaneous
1.75mg
As needed (45 min before) · PRN, max 8x/month
subcutaneous (research)
500-1500mcg
Daily · 8-16 weeks
Benefits
FDA-approved
Works in 45 minutes
Non-hormonal
Central arousal mechanism
Both sexes respond
Side Effects
Nausea (40%)
Facial flushing
Injection reactions
Headache
Vomiting
Key Research
PT-141 RECONNECT trials
Significant improvements in sexual desire in women with HSDD
PT-141 in men
Demonstrated efficacy for erectile dysfunction before focus shifted to women
Regulatory Status
FDA-approved as Vyleesi for HSDD in premenopausal women. Prescription required.
Contraindications
- ⚠Uncontrolled hypertension
- ⚠Cardiovascular disease
- ⚠Pregnancy
- ⚠Nausea sensitivity
GLP-1 users experiencing sexual side effects may discuss PT-141 with healthcare provider.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.